CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
Beginning June 1, 2020 all 5 CTS laboratories will being transitioning from the Grifols Procleix Ult...
CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The ...
As communicated on January 21, 2020, CTS will implement the licensed Grifols Babesia test for sample...
On May 9, 2019 the Food and Drug Administration issued a “Recommendations for Reducing the Ris...
As a service to our partners, CTS provides a copy of all licenses and accreditations on our website....
On April 29, 2019, CTS will begin performing Donor-Screen HLA® Class I and II testing on the Str...